The interaction between ATP-sensitive K+ chan nels (K ATP ) and nitric oxide (NO) was studied in pial arterioles of piglets. We examined the effects of �-nitro-L-arginine methyl ester (L-NAME), a general inhibitor of nitric oxide syn thase (NOS), and 7-nitroindazole (7-NI), a selective inhibitor of neuronal NOS, on aprikalim-induced cerebral vasodilation.
and 7-NI reduced the vasodilator responses to 10-4 M N methyl-D-aspartate (NMDA) (by 73% and by 36%, respec tively). Furthermore, 7-NI treatment abolished the glutamate induced dilatation of pial arterioles. Administration of L NAME reduced the NOS activity in the cerebral cortex by 88%, whereas the reduction after the 7-NI treatment was 44%. Pre treatment and coadministr;ttion of 10-5 M glibenclaminde, a specific inhibitor of K ATP or L-NAME administration, did not change the dilatory response to sodium nitroprusside. We con clude that NO may be involved in aprikalim-induced dilation of pial arterioles. Key Words: Glibenclamide-Aprikalim Glutamate-NMDA-Nitric oxide synthase. duces vasodilatation to acetylcholine (Macfarlane et aI., 1991; Clavier et aI., 1994) and NMDA (Busija et aI., 1996) . Recently we have found that ischemia impairs the vasorelaxant effect of aprikalim, a specific opener of KATP (Busija and Louis, 1995) .
It is generally accepted that activation of KATP results in hyperpolarization and, thus, relaxation of vascular smooth muscle. However, recent experiments indicate that compounds that open KATP can induce vasorelax ation by mechanisms that are partly independent of hy perpolarization (Quast et al., 1994) . Despite definite ad vances in the understanding of potassium channel induced vasorelaxation, an important question remains unanswered: does NO contribute to pial arteriolar dila tation induced by potassium channel openers?
The finding that glibenclamide, an inhibitor of KATP ' inhibits hyperpolarization to NO is a novel observation in rabbit and rat mesenteric arteries (Garland and Mc Pherson, J 992; Murphy and Brayden, 1995) . It suggests that a reciprocal relationship between KATP and NO may exist and that K+ channel activation may be a mechanism for the vasorelaxant effect of NO.
The first goal of this study was to determine whether vasorelaxation induced by aprikalim, through activation of KATP, is dependent on production of NO. We com-pared the effects of � -nitro-L-arginine methyl ester (L NAME), an inhibitor of nitric oxide synthase (NOS), and 7-nitroindazole (7-NI), a putative inhibitor of neuronal NOS, on aprikalim-induced cerebral vasodilatation. In addition, we determined the effects of administration of 7-NI on glutamate-induced and NMDA-induced dilata tion of pial arterioles. Further, we examined the hypoth esis that dilatation of cerebral arterioles to exogenous NO is mediated by KAT P '
MATERIALS AND METHODS
Newborn (1-7 days old) piglets of either sex with a body weight of 0.9-1.4 kg, were used in this study. Anesthesia was induced with sodium thiopental (30 mg/kg) followed by intra venous injection of a-chloralose (75 mg/kg). Supplemental doses of a-chloralose were given as needed to maintain a stable level of anesthesia. Animals were intubated via tracheotomy and artificially ventilated with room air. Rectal temperature was maintained at 37-38°C by a heating pad. Systemic arterial blood pressure was recorded via a right femoral artery cannula connected to a pressurc transducer. The right femoral vein was cannulated for drug administration. The heads of the piglets were fixed in a stereotaxis frame. The scalp was incised and connective tissue over the parietal bone was removed. A 19mm craniectomy for a stainless steel-glass cranial window was made in the left parietal bone, 10 mm rostral to the coronal suture. The dura was exposed, cut, and retlected over the skull.
The cranial window with three needle ports was placed into the hole, sealed by bone wax and cemented with SuperGlue and dental acrylic. The closed window was filled with artificial cerebrospinal tluid (aCSF), which was warmed to 37°C and equilibrated with 6% O2 and 6.5% CO2 in N2 gas mixture. The composition of the aCSF was as follows (millimolar): KCI 2.9, MgCl2 1.4, CaCI2 1.2, NaCI 132, NaHC03 24.6, urea 6.7, and glucose 3.7. Diameters of pial arterioles were measured using a microscope (Wild M36, Switzerland) equipped with a video camera (Panasonic, Japan) and video micro scaler (IY-550, For-A Co. Newton, MA, U.S.A.). Following the surgical pro cedure the cranial window was gently infused with aCSF sev eral times until a stable baseline arteriolar measurement was obtained.
Protocols
In the first group (n = 6), we tested whether aprikalim elicits reproducible dilatation of pial arterioles over time. Arteriolar responses were determined to topically applied aprikalim of 10-6 and 10-8 M during control conditions and 45 min after the vessel diameter returned to baseline.
To examine the effect of inhibition of NOS on the aprikalim evoked vasodilatation, we used two experimental groups. In one group (n = 8), we measured the change in diameter of pial arterioles (-100 f.Lm in diameter) to topical aprikalim (10-8 and 10-6 M) before, and 45 min after L-NAME administration (15 mg/kg, i.v.). To verify the effectiveness of the L-NAME treat ment, we evaluated the NMDA-evoked (10-4 M) vasodilatation before and after the administration of L-NAME. In the other group (n = 6), changes in arteriolar diameters to 10-8 and 10-6 M of aprikalim were measured under control conditions and 45 min after 7-NI administration (50 mg/kg, i.p.).
In a separate group of animals (n = 4), we examined vas cular responses to topical sodium nitroprusside (SNP) at doses of 10-6 and 10-5 M prior to and 45 min after L-NAME admin istration (15 mg/kg, i.v.) , to test the specific effect of NOS inhibition.
In another group (n = 7) arteriolar responses were deter mined in response to 10-4 M glutamate and to 10-4 M NMDA before and 45 min after the 7-NI treatment. In the final group of piglets (n = 9), we examined whether dilator responses of the pial arterioles to NO were mediated by K ATP' We deter mined changes in vessel diameter to topical SNP at doses of 10-6 and 10-5 M before and in the presence of glibenclamide (10-5 M), an inhibitor of K ATP ' In a previous study we have shown that dilatation to aprikalim was completely inhibited when pretreated and coadministered with 10-5 M gliben clamide (Busija and Louis, 1995) .
Nitric oxide synthase activity ex vivo was measured by quantification of the conversion of [14Cl-citrulline from L-C4C]arginine using a modified method (Meng et aI., 1995) based on principles described by Bredt and Snyder (1989) . 
Statistics
Data are expressed as mean ± standard deviation (SD). A paired t test was used for comparing data between two groups.
For repeated measurement analysis, analysis of variance (ANOY A) was used, and the Student-Newman-Keuls test was then performed. Data analyses were performed on absolute and percent change data. A p value <0.05 was regarded as statisti cally significant.
RESULTS
Under control conditions, mean arterial blood pressure was similar in the various groups of animals (57 ± 4 mm Hg, n = 40). Arterial blood gases and pH were moni tored regularly throughout the experiment and were kept in the physiological range (Peo 2 = 33 ± 3 mm Hg, P0 2 = 87 ± 7 mm Hg and pH = 7.44 ± 0.03, n = 40). Administration of aprikalim resulted in dose-depen dent arteriolar dilatation (Table 1 ). In the time-control group, 10-8 and 10-6 M aprikalim dilated pial arterioles 
Ll diameter ( by 10 ± 3% and 21 ± 4%, respectively, at the first ap plication. Arteriolar dilatation to aprikalim did not change over time. It dilated by 10 ± 5% and 20 ± 5% with the second application (Table l) .
Intravenous administration of L-NAME resulted in an immediate but transient elevation of systemic blood pres sure. In this group baseline mean arterial blood pressure was 54 ± 4 mm Hg. Twenty minutes after the L-NAME administration the arterial blood pressure was 75 ± 8 mm Hg and diameter of the arterioles was 86 ± 8 /-Lm, 15% less than baseline value. Forty-five minutes after L NAME administration the arterial blood pressure stabi lized at 64 ± 9 mm Hg. In these animals administration of L-NAME reduced arteriolar dilation to aprikalim (Table 1, Fig. 1 ). Both absolute and percent changes indicated a significant reduction in the dilative responses. The percent changes to 10-8 M and 10-6 M aprikalim were 4 ± 4% and 12 ± 7%, respectively (Table I, Fig. I) .
Arteriolar dilatations to 10-4 M NMDA were almost completely inhibited (percent changes were 18 ± 5% before and 5 ± 4% after, p < 0.05, Fig. I) .
Intraperitoneal administration of 7-NI (50 mglkg) had no effect on systemic blood pressure and on pial arterial diameters. Administration of 7-NI reduced the vasodila tor activity of glutamate (10-4 M) and NMDA (10-4 M).
The dilatory responses were 17 ± 8% and 29 ± 10% in control circumstances and 2 ± 6% and 16 ± 10% after drug application, respectively. However, the vasodilator responses to 10-8 and 10-6 M aprikalim were not reduced (Table 1, Fig. 2) . After intravenous administration of L-NAME cerebral cortical NOS activity (0.39 ± 10 pmol mg protein-I min-I ) was decreased by about 90% in comparison with the un treated animals (3.34 ± 0.59 pmol mg protein-I min-I ). In animals treated with 7-NI, the NOS activity was reduced by 44% (1.84 ± 0.32 pmol mg protein-I min-l ).
Dilatation of cerebral arterioles in response to SNP was not affected by L-NAME treatment. The increase in diameter was 17 ± 1 % and 31 ± 5% before, and 17 ± 1 % and 32 ± 2% 45 min after the L-NAME administration (n = 4). Pretreatment and coadministration of 10-5 M gliben clamide, an inhibitor of A TP-sensitive potassium chan nels, did not change the response to SNP (Table 1, 3). In this group (n = 9) 10-6 and 10-5 M SNP dilated pial arterioles by 17 ± 5 and 30 ± 7% prior to and by 16 ± 4% and 28 ± 6% after glibenclamide, respectively. Administration of glibenclamide did not alter resting ar teriolar diameter (101 ± 12 f.Lm in the absence and 102 ± 13 f.Lm in the presence of glibenclamide, n = 9).
DISCUSSION
The major findings in the present study are the fol lowing: (1) inhibition of NOS by L-NAME reduces apri kalim-induced dilation of pial arterioles; (2) inhibition of neuronal NOS by 7-NI has no influence on the aprika lim-induced dilatation; and (3) inhibition of KATP by glibenclamide has no influence on the vasodilator effect Compounds that open K+ channels have a variety of potential therapeutic actions, and they are under inten sive investigation (Quast, 1992; Challinor-Rogers and McPherson, 1994) . The detailed molecular basis of the mechanism of action of KATP openers is unknown at the present time (Quast et aI., 1994) . The binding site of these compounds has been difficult to identify. There is also a discrepancy between the concentrations required to cause vasodilatation and those needed to observe 4 2 K+ efflux in vascular smooth muscle. Usually a 10-30 times higher concentration is needed to observe tracer efflux than to elicit vasodilatation (Atwal, 1994) . These facts point out that additional mechanisms may also be in- volved in vasodilatation caused by KA TP openers (Quast et aI., 1994) . In our study 10-8 and 10-6 M aprikalim dilated pial arterioles by 10-2 1 % in control conditions. These mag nitudes of dilatation are similar to those found by May han and and to our previous results (Busija and Louis, 1995) . We do not know why the dose response curve for aprikalim is relatively flat compared to other stimuli. Similar response profiles have been found for other agents such as glutamate (Meng et aI., 1995) , acetylcholine (Rosenblum et aI., 1992) , and bra dykinin (Baumbach et aI., 1994) . In addition, it is worth noting that pial arteriolar dilation by 20% would reduce vascular resistance by one half.
We hypothesized that NO may also play a role in the vasorelaxation response to aprikalim. This view is sup ported by the results of some, but not all, investigations. For example, Mayhan and Faraci, 1993 showed a slight, but not significant impairment in dilatation to aprikalim after W-monomethyl-L-arginine application in rats. In addition, Gardinier et al. (1991) reported that in most organs hemodynamic responses to levcromacalim were independent of NO-mediated mechanisms in awake rats. However, inhibition of NO synthesis reduced the dilation responses to levcromacalim in the mesenteric circulation. On the other hand, Randall and Griffith (1993) and Ran dall et al. (1994) found that L-NAME treatment increased the vasodilator potency of levcromakalim but not that of pinacidil in isolated rabbit ear arteries.
We found that intravenous L-NAME consistently re duced aprikalim-induced pial arteriolar dilatation. The mechanisms that may account for reduced responses of J Cereb Blood Flow Metab. Vol. 16, No.6. 1996 pial arterioles to aprikalim after L-NAME treatment are unclear but might include modification of the binding capacity or affinity of ligands by L-NAME or a syner gism between basal NO production and effects of KATP openers (Rae and Correa, 1992) . For example, opening a few K+ channels results in a minor change in the mem brane potential of endothelial cells, which is sufficient to trigger a series of reactions leading to marked NO dependent vasorelaxant effects. However, our present data indicate that vasodilation to SNP remains intact af ter L-NAME treatment. This finding, in agreement with Koenig et al. (1994) , confirms that inhibition of NOS by L-NAME blocks NO generation but not NO action.
Increasing evidence suggests that NO participates in the maintenance of resting cerebral blood flow but the sources of NO remain to be elucidated. Both endothelial and neuronal-derived NO may participate, but their rela tive contribution differs depending on animal species, brain region, and segment of cerebral vasculature (ladecola et aI., 1994) . Data obtained from experiments using various NOS inhibitors suggest that the route of administration and timing of drug treatment influences pial arteriolar tone. Experiments by Armstead et al (1994) and Armstead (1995) showed that topically ap plied L-NA'or L-NNA reduced pial arteriolar diameter. In contrast, Meng et al. (1995) did not find significant changes in pial arteriolar diameter when using 10-6 M L-NNA topically. Furthermore, experimental evidence indicates that the age of the animal (Traystman et aI., 1995) and the type of anesthetic also influence baseline blood pressure and the time course of changes in mean arterial blood pressure after systematic application of L NAME (Gibson et aI., 1994) . In our experiments we found an elevation in mean arterial blood pressure of 20% 45 min after application of L-NAME. Because of the interanimal variation, this increase was not statisti cally significant.
In the present study, we evaluated how two different inhibitors of NO synthase affect pial arteriolar diameter. Intravenous administration of L-NAME was followed by an immediate elevation of blood pressure and constric tion of pial arterioles. However, pial arteriolar diameter returned to baseline 45 min after drug application. At the same time, cortical NOS activity was reduced by 88%. This observation supports the hypothesis that after inhi bition of NOS a normal cerebral metabolism can be maintained (Iadecola and Xu, 1994; Kozniewska et aI., 1992) . Considering a continuous basal NO release that is sensitive to L-NAME, other vasodilator mechanisms could compensate for the lack of NO. Compared with L-NAME, administration of 7-NI did not produce any alteration in the arterial blood pressure or in the cerebral vascular tone. We conclude that aprikalim-induced pial arteriolar dilatation is mediated partly by nonneuronally derived NO.
Because L-NAME inhibits all unknown isofonns of NO synthase, it is impossible to identify the source of NO (Moncada, 1993) . 7-NI appears to be a selective inhibitor for neuronal NOS (Faraci and Brian, 1995) . Yoshida et al. (1994) reported, that 7-NI treatment in the range of 25-100 mg/kg causes a dose-independent, ap proximately 50% reduction of NOS activity in the fore brain, and this remained stable until 120 min after drug application. In three animals we gave an additional 25 mg/kg of 7-NI 45 min after the first 7-NI application and tested the vascular responses to aprikalim and glutamate. We did not observe any additional effect of 7-NI. Thus, we postulate that aprikalim-induced vasodilatation is me diated through endothelial NO rather than neuronal NO.
Our present data support previous findings that dila tation of pial arterioles in response to glutamate and NMDA are sensitive to NOS inhibition (Meng et aI., 1995; Faraci and Brian, 1995) . Furthermore, our results give the first direct evidence that glutamate-induced va sodilatation could be blocked by inhibition of neuronal NOS. The observation that NMDA-induced vasodilata tion was less sensitive to the selective inhibition of neu ronal NOS suggests that a reduced NOS activity is still enough to mediate vasodilation when NMDA receptors are activated.
The selective neuronal NOS inhibitor, 7-NI, may open novel therapeutic strategies in the neurodegenerative dis eases. Several studies suggest that NO of neuronal origin contributes to cell death following cerebral · ischemia or anoxia, but the mechanisms are unknown (Dalkara et aI., 1994) . Some evidence suggests that neurotoxicity in cludes the interaction of NO with superoxide radical forming peroxynitrite. A novel observation of Schulz et al. (1995) indicated that 7 -NI protects against I-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MTPT) -induced neurotoxicity. In another study (Yoshida et aI., 1994) , it has been shown that 7-NI decreased infarction size when given 5 min after occlusion of the middle cerebral artery in rats. On the other hand, hemodynamic responses to glutamate or NMDA may play a role in excitotoxic brain injury (Dalkara et aI., 1994) . We conclude that selective neuronal NOS inhibition can reduce the glutamate induced and NO-mediated cerebral injury.
In our experiments large doses (50 mg/kg) of 7-NI had no effect on blood pressure and did not change pial ar teriolar diameter, whereas NOS activity in the cerebral cortex decreased by 44%. In a previous study by Kelly et al. (1995) , inhibition of neuronal NOS by 7-NI decreased cerebral blood flow, which was measured by an autora diographic technique. Their result is in conflict with our present finding and other reports of Yoshida et al. (1994) and Faraci and Brian (1995) . These authors, using a cra nial window preparation, have reported that 7-NI had no effect on the diameter of pial arterioles. The discrepancy between the different results probably reflects species and methodological differences.
NO is thought to relax vascular smooth muscle by stimulation of guanylate cyclase, increasing levels of cOMP, cOMP-dependent phosphorylation of a protein kinase, and kinase-dependent phosphorylation of various targets. The end result is a decreased calcium sensitivity of the contractile apparatus. In a recent report by Kubo et al. (1994) , patch clamp analyses demonstrated that the open probability of individual KA TP channels could be increased by cOMPo Thus we considered the possibility that inhibition of KA TP would influence the pial arteriolar dilatation to SNP. Tn the current study KA TP was blocked by 10-5 M glibenclamide. This dose of gJibenciamide has completely blocked pial arteriolar dilatation activated di rectly by aprikalim (Busija and Louis, 1995) and inhib ited CORP-induced vasodilatation as well (Louis et aI., 1996) . The finding that glibenclamide had no effect on SNP-evoked pial arteriolar dilatation matches similar findings in rabbits and rats. In those studies even a higher dose (10-3 M) of glibenclamide did not affect vasodila tation evoked by nitroglycerin or SNP (Faraci and Hei stad, 1993; Faraci et aI., 1994) . Conversely, Annstead (1996) reports that 10-6 M glibenclamide attenuates SNP-induced dilatation of small pial arteries and arteri oles. We do not know why these differences are present. Although the exact reason for this discrepancy remains unclear, it may be due to different timing in drug admin istration and differences in the basal diameter of the ves sels under investigation.
In the present study, topical application of 10-5 glib enclamide had no influence on baseline diameter of the pial arterioles. This finding is in agreement with the ob servations of Faraci and Heistad (1993) and provide fur ther evidence that activity of KA TP had no effect on the basal tone of pial arterioles. However, our result differs from results of Jackson (1993) , who reported that glib enclamide produced concentration-dependent vasocon striction in hamster cheek arterioles. Similarly, Clapp and Ourney (1992) found that KA TP channels regulate resting potential of pulmonary arteriolar smooth muscle cells. The disparate results reveal regional and species differences in the physiological role of arteriolar KA TP channels.
In summary, we found that inhibition aprikalim induced dilatation of pial arterioles is mediated partly by NO. The source of NO is likely the vascular endothe lium.
